Data

Data from: Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian Aboriginal community

The University of Western Australia
Kearns, Therese M. ; Ward, Linda ; Holt, Deborah C. ; Currie, Bart J. ; Gundjirryirr, Roslyn ; Bundhala, Leanne ; Chatfield, Mark ; Andrews, Ross M. ; Speare, Richard ; Cheng, Allen C. ; McCarthy, James ; Carapetis, Jonathan R. ; Shield, Jennifer
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.5061/dryad.014v6&rft.title=Data from: Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian Aboriginal community&rft.identifier=10.5061/dryad.014v6&rft.publisher=DRYAD&rft.description=Background: Scabies is endemic in many Aboriginal and Torres Strait Islander communities, with 69% of infants infected in the first year of life. We report the outcomes against scabies of two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community. Methods: Utilizing a before and after study design, we measured scabies prevalence through population census with sequential MDAs at baseline and month 12. Surveys at months 6 and 18 determined disease acquisition and treatment failures. Scabies infestations were diagnosed clinically with additional laboratory investigations for crusted scabies. Non-pregnant participants weighing ≥15 kg were administered a single 200 μg/kg ivermectin dose, repeated after 2–3 weeks if scabies was diagnosed, others followed a standard alternative algorithm. Principal Findings: We saw >1000 participants at each population census. Scabies prevalence fell from 4% at baseline to 1% at month 6. Prevalence rose to 9% at month 12 amongst the baseline cohort in association with an identified exposure to a presumptive crusted scabies case with a higher prevalence of 14% amongst new entries to the cohort. At month 18, scabies prevalence fell to 2%. Scabies acquisitions six months after each MDA were 1% and 2% whilst treatment failures were 6% and 5% respectively. Conclusion: Scabies prevalence reduced in the six months after each MDA with a low risk of acquisition (1–2%). However, in a setting where living conditions are conducive to high scabies transmissibility, exposure to presumptive crusted scabies and population mobility, a sustained reduction in prevalence was not achieved. Clinical Trial Registration: Australian New Zealand Clinical Trial Register (ACTRN—12609000654257).,Scabies_Repository_finalScabies infestation status of human participants from a remote Aboriginal community in Northern Australia.,&rft.creator=Kearns, Therese M. &rft.creator=Ward, Linda &rft.creator=Holt, Deborah C. &rft.creator=Currie, Bart J. &rft.creator=Gundjirryirr, Roslyn &rft.creator=Bundhala, Leanne &rft.creator=Chatfield, Mark &rft.creator=Andrews, Ross M. &rft.creator=Speare, Richard &rft.creator=Cheng, Allen C. &rft.creator=McCarthy, James &rft.creator=Carapetis, Jonathan R. &rft.creator=Shield, Jennifer &rft.date=2016&rft.relation=http://research-repository.uwa.edu.au/en/publications/2ad866cd-564f-40ec-986e-2965c2c6c746&rft.type=dataset&rft.language=English Access the data

Access:

Open

Full description

Background: Scabies is endemic in many Aboriginal and Torres Strait Islander communities, with 69% of infants infected in the first year of life. We report the outcomes against scabies of two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community. Methods: Utilizing a before and after study design, we measured scabies prevalence through population census with sequential MDAs at baseline and month 12. Surveys at months 6 and 18 determined disease acquisition and treatment failures. Scabies infestations were diagnosed clinically with additional laboratory investigations for crusted scabies. Non-pregnant participants weighing ≥15 kg were administered a single 200 μg/kg ivermectin dose, repeated after 2–3 weeks if scabies was diagnosed, others followed a standard alternative algorithm. Principal Findings: We saw >1000 participants at each population census. Scabies prevalence fell from 4% at baseline to 1% at month 6. Prevalence rose to 9% at month 12 amongst the baseline cohort in association with an identified exposure to a presumptive crusted scabies case with a higher prevalence of 14% amongst new entries to the cohort. At month 18, scabies prevalence fell to 2%. Scabies acquisitions six months after each MDA were 1% and 2% whilst treatment failures were 6% and 5% respectively. Conclusion: Scabies prevalence reduced in the six months after each MDA with a low risk of acquisition (1–2%). However, in a setting where living conditions are conducive to high scabies transmissibility, exposure to presumptive crusted scabies and population mobility, a sustained reduction in prevalence was not achieved. Clinical Trial Registration: Australian New Zealand Clinical Trial Register (ACTRN—12609000654257).,Scabies_Repository_finalScabies infestation status of human participants from a remote Aboriginal community in Northern Australia.,

Notes

External Organisations
Royal Darwin Hospital; James Cook University; Monash University (Australia); Queensland Institute of Medical Research; La Trobe University
Associated Persons
James McCarthy (Creator)Therese M. Kearns (Creator); Linda Ward (Creator); Deborah C. Holt (Creator); Bart J. Currie (Creator); Roslyn Gundjirryirr (Creator); Leanne Bundhala (Creator); Mark Chatfield (Creator); Ross M. Andrews (Creator); Richard Speare (Creator); Allen C. Cheng (Creator); Jennifer Shield (Creator)

Issued: 2016-10-12

This dataset is part of a larger collection

Click to explore relationships graph

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers